Why a Cheap CPM Can Produce an Expensive Pharma Outcome
A worked example showing how media price, target reach, quality, and outcome rate combine, and why the lowest CPM often costs more per result in pharma.
The short answer
A low CPM is only cheap if the impressions reach the right people in conditions where they can be seen and acted on. In pharma, where audiences are narrow and outcomes are rare, the gap between price per thousand impressions and cost per meaningful result is often large. A $12 CPM can easily cost more per engaged prescriber than a $45 CPM.
The fix is not to ignore price. It is to decompose cost into the parts that actually drive value.
Break cost per outcome into four parts
Cost per outcome can be written as a chain:
Cost per outcome = CPM ÷ 1,000 ÷ (share on target) ÷ (share that is quality) ÷ (outcome rate among quality on-target impressions)
Each part is a place where a cheap buy can lose value:
| Factor | What it means | Where cheap supply often loses |
|---|---|---|
| CPM | Price paid per thousand impressions | Looks best on the rate card |
| On-target share | Share of impressions reaching the intended audience | Broad or modeled audiences dilute it |
| Quality share | Share that is viewable, valid, and in suitable context | Low-quality supply and made-for-advertising sites |
| Outcome rate | Share of quality on-target impressions leading to the outcome | Weak context and poor frequency control |
Hypothetical worked example
Compare two HCP display buys. All numbers are illustrative.
| Buy A | Buy B | |
|---|---|---|
| CPM | $12 | $40 |
| Share on verified target list | 25% | 80% |
| Share viewable and valid | 50% | 75% |
| Quality on-target impressions per $1,000 | 10,417 | 15,000 |
| Effective cost per 1,000 quality on-target impressions | $96 | $67 |
Buy A is less than a third of the price per impression. Once you account for audience accuracy and quality, it costs roughly 45% more per impression that could matter. If context or frequency also affects the outcome rate, the gap can widen further.
Why the cheap number keeps winning
Cheap CPMs are visible in every report. On-target share and quality share are harder to get and often come from different sources. Match rates come from one partner, viewability from a verification vendor, and outcomes from a measurement study months later. The number that is easiest to see ends up driving optimization.
A few habits help:
- Report effective cost alongside CPM. Even an approximate effective cost per quality on-target impression changes conversations.
- Ask for denominators. "80% on target" means nothing unless you know on target against what list and measured how. See HCP target-list reach measurement.
- Watch for fee shifting. A low media CPM can hide high data or tech fees elsewhere. See working media vs. nonworking costs.
When a cheap CPM is the right choice
Low-cost reach is not always wrong. For broad DTC awareness in a large condition category, a cheaper, broader buy can be the most efficient way to build reach, as long as quality is controlled. The point is to choose it on purpose, with the decomposition in view, not because it looks best on a rate card.
Limits of the decomposition
The four factors are not fully independent. Higher-quality environments can raise the outcome rate, and some outcome effects come from frequency across channels rather than any single buy. Treat the chain as a diagnostic, not an exact formula. Where you have outcome data, compare attributed and incremental results before concluding one buy is more efficient.
Practical takeaway
Add one column to your partner report: estimated cost per 1,000 quality, on-target impressions. Use your best available inputs and label them. It will not be perfect, but it will stop the cheapest CPM from winning by default.
Sources
- Media Rating Council, Standards and Guidelines
- ANA, Programmatic Media Supply Chain Transparency Study
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.